Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 28, 2020 01:00 ET | Source: INNATE PHARMA

First Patient Dosed in Avdoralimab Phase II Clinical Trial in COVID-19 Patients With Severe Pneumonia

MARSEILLE, France, April 28, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was...
April 24, 2020 10:30 ET | Source: INNATE PHARMA

Innate Pharma Files Its 2019 Universal Registration Document (Document d’enregistrement universel) and Its 2019 Annual Report on Form 20-F

MARSEILLE, France, April 24, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2019...
April 24, 2020 10:30 ET | Source: INNATE PHARMA

Innate Pharma Files Its 2019 Universal Registration Document (Document d’Enregistrement Universel) and Its 2019 Annual Report on Form 20-F

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2019 Universal Registration Document (Document d’enregistrement...
April 24, 2020 10:30 ET | Source: INNATE PHARMA

Innate Pharma Publie Son Document d’Enregistrement Universel 2019 Et Son Rapport Annuel 2019 Sur « Form 20-F »

Innate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce que son Document d’enregistrement universel pour l’année 2019 a été déposé auprès...
April 14, 2020 01:00 ET | Source: INNATE PHARMA

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 19, 2020 Without the Physical Presence of Its Shareholders

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on May 19, 2020 AM in its headquarters, 117 avenue de Luminy, F-13009...
April 14, 2020 01:00 ET | Source: INNATE PHARMA

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 19, 2020 Without the Physical Presence of Its Shareholders

MARSEILLE, France, April 14, 2020 (GLOBE NEWSWIRE) -- Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on May 19, 2020...
April 14, 2020 01:00 ET | Source: INNATE PHARMA

Innate Pharma Annonce La Tenue De Son Assemblée Générale Annuelle Le 19 Mai 2020 À Huis Clos

Innate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce la tenue de son Assemblée Générale annuelle, à huis clos, le 19 mai 2020, au siège...
March 10, 2020 02:00 ET | Source: INNATE PHARMA

Innate Pharma Reports Full Year 2019 Financial Results and Business Update

Innate globally expands its capital markets presence with a successful NASDAQ IPO and Global Offering that provided gross proceeds of $79.1 million (€71.5 million1)Monalizumab to advance to a Phase...
March 10, 2020 02:00 ET | Source: INNATE PHARMA

First Patient Dosed in IPH5201 Phase I Clinical Trial in Advanced Solid Tumors

MARSEILLE, France, March 10, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was...
March 10, 2020 02:00 ET | Source: INNATE PHARMA

First patient dosed in IPH5201 Phase I clinical trial in advanced solid tumors

Anti-CD39 monoclonal antibody, IPH5201, advances to first-in-human clinical trial; first molecule from Innate/AstraZeneca expanded collaboration progressing to the clinic Innate Pharma SA (Euronext...